Clinical-stage immunotherapy firm ImmunityBio (NASDAQ: IBRX), completes accrual of the first two phases of a national trial assessing its Nant Cancer Vaccine (NCV) in participants with Lynch syndrome.

Utilising a tri-valent Adenovirus (Tri-Ad5) combined with IL-15 superagonist N-803, the trial aims to prevent colon and other cancers.

Lynch syndrome, associated with a genetic mutation, elevates cancer risks.

ImmunityBio's study progresses to the randomised controlled phase, aiming to enroll up to 186 individuals.

The vaccine targets cancer-specific proteins to activate natural killer and T cells for potential cancer prevention. ImmunityBio's investigational Tri-Ad5 Vaccines and N-803 continue to be studied for safety and efficacy, with a focus on preventing colorectal and other cancers associated with Lynch syndrome.